
至 2028 年亚太地区结直肠癌市场预测 – COVID-19 影响和区域分析 – 按模式(诊断类型、治疗类型和影像类型)和最终用户(医院和诊断与研究实验室)
No. of Pages: 185 | Report Code: TIPRE00009518 | Category: Life Sciences
No. of Pages: 185 | Report Code: TIPRE00009518 | Category: Life Sciences
新兴经济体不断增长的制药行业正在为重要参与者创造利润丰厚的机会扩大其在亚太结直肠癌市场的业务。印度制药行业预计将从2021年的420亿美元增长到2025年的550亿美元;预计2021年至2025年复合年增长率为37%。根据印度品牌公平基金会(IBEF)2019年4月的统计数据,印度是全球最大的仿制药供应国。印度制药业满足了美国约 40% 的仿制药需求,约占英国多种疫苗需求的 50% 和 25% 的药品需求。此外,印度拥有大量科学家和工程师,有潜力显着发展医疗保健行业。
主要结直肠癌市场参与者专注于新加坡和印度等新兴市场。中国有很多结直肠癌患者,医疗旅游业也不断增长。根据澳大利亚健康与福利研究所的数据,2021 年诊断出超过约 15,540 例结直肠癌新病例。此外,根据马来西亚医疗旅游理事会的数据,2019 年有超过 122 万名旅客前往马来西亚进行医疗保健。亚太地区治疗成本低廉,加上先进技术的采用,可减少手术等待时间,这可能会增加结直肠癌相关手术的数量。这最终会增加对结直肠癌诊断和治疗的需求。
因此,新兴国家不断增长的医疗旅游业和不断增长的制药业预计将推动亚太地区结直肠癌的发展市场增长;预计在预测期内将为市场运营商提供重大增长机会。
借助新功能和技术,供应商可以吸引新客户并扩大他们在新兴市场的足迹。这一因素可能会推动亚太地区结直肠癌市场的发展。亚太地区结直肠癌市场预计在预测期内将以复合年增长率大幅增长。
亚太地区结直肠癌市场按模式、最终用户和国家进行细分。根据治疗方式,亚太结直肠癌市场分为诊断类型、治疗类型和影像类型。 2022年,诊断类细分市场占据最大的市场份额,预计在预测期内复合年增长率最高。根据最终用户,亚太地区结直肠癌市场分为医院和诊断与治疗。研究实验室。 2022年,医院细分市场占有更大的市场份额。按国家/地区划分,亚太地区结直肠癌市场分为澳大利亚、中国、印度、日本、韩国和亚太地区其他地区。 2022年,中国占据最大市场份额。
雅培、安进公司、布鲁克公司、Clinical Genomics Technologies Pty Ltd.、EDP Biotech Corporation、Epigenomics AG、F. Hoffmann-La Roche AG、Quest Diagnostics 和 VolitionRx Limited 是亚太结直肠癌市场的领先公司。
Strategic insights for Asia Pacific Colorectal Cancer involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 3,864.66 Million |
Market Size by 2028 | US$ 5,169.04 Million |
Global CAGR (2022 - 2028) | 3.7% |
Historical Data | 2020-2021 |
Forecast period | 2023-2028 |
Segments Covered |
By 方式
|
Regions and Countries Covered | 亚太地区
|
Market leaders and key company profiles |
The regional scope of Asia Pacific Colorectal Cancer refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Colorectal Cancer Market is valued at US$ 3,864.66 Million in 2022, it is projected to reach US$ 5,169.04 Million by 2028.
As per our report Asia Pacific Colorectal Cancer Market, the market size is valued at US$ 3,864.66 Million in 2022, projecting it to reach US$ 5,169.04 Million by 2028. This translates to a CAGR of approximately 3.7% during the forecast period.
The Asia Pacific Colorectal Cancer Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Colorectal Cancer Market report:
The Asia Pacific Colorectal Cancer Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Colorectal Cancer Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Colorectal Cancer Market value chain can benefit from the information contained in a comprehensive market report.